Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)

Cardiac remodeling, which typically results from chronic hypertension or following an acute myocardial infarction, is a major risk factor for the development of heart failure and, ultimately, death. The renin-angiotensin system ( RAS) has previously been established to play an important role in the progression of cardiac remodeling, and inhibition of a hyperactive RAS provides protection from cardiac remodeling and subsequent heart failure. Our previous studies have demonstrated that overexpression of angiotensin-converting enzyme 2 ( ACE2) prevents cardiac remodeling and hypertrophy during chronic infusion of angiotensin II ( ANG II). This, coupled with the knowledge that ACE2 is a key enzyme in the formation of ANG-( 1-7), led us to hypothesize that chronic infusion of ANG-( 1-7) would prevent cardiac remodeling induced by chronic infusion of ANG II. Infusion of ANG II into adult Sprague-Dawley rats resulted in significantly increased blood pressure, myocyte hypertrophy, and midmyocardial interstitial fibrosis. Coinfusion of ANG-( 1-7) resulted in significant attenuations of myocyte hypertrophy and interstitial fibrosis, without significant effects on blood pressure. In a subgroup of animals also administered [ D-Ala(7)]-ANG-( 1-7) ( A779), an antagonist to the reported receptor for ANG-( 1-7), there was a tendency to attenuate the antiremodeling effects of ANG-( 1-7). Chronic infusion of ANG II, with or without coinfusion of ANG-( 1-7), had no effect on ANG II type 1 or type 2 receptor binding in cardiac tissue. Together, these findings indicate an antiremodeling role for ANG-( 1-7) in cardiac tissue, which is not mediated through modulation of blood pressure or altered cardiac angiotensin receptor populations and may be at least partially mediated through an ANG-( 1-7) receptor.